(This article was originally published at Simply Statistics, and syndicated at StatsBlogs.)
On the heals of the failed Illumina deal, another bare-knuckled brawl.
GlaxoSmithKline plans to take its bid for Human Genome Sciences directly to shareholders this week, after being rejected by the biotechnology company last month.
Please comment on the article here: Simply Statistics
